Hexobarbital

Summary

Hexobarbital (CHEMBL7728) is an approved small molecule (ATC N01AF02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N01AF02 (+1 more)
• Chemistry: 236.27 Da · C12H16N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL7728
Name	Hexobarbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3608
ChEBI	CHEBI:5706
ATC	N01AF02, N05CA16
Molecular formula	C12H16N2O3
Molecular weight	236.27
InChIKey	UYXAWHWODHRRMR-UHFFFAOYSA-N

SMILES: CC1(C(=O)NC(=O)N(C1=O)C)C2=CCCCC2

IUPAC name: 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione

ChEBI definition: A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.

Also known as: Hexobarbital, Hexobarbital ciii, NSC-71929, hexobarbitone, SID29215369, SID47194291, SID26754503, SID144205214, SID170465860, HEXOBARBITAL

Parent form; salt/anhydrous children: CHEMBL2104880

Patent coverage: 2,376 distinct patent families (6,775 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Menin/Histone-lysine N-methyltransferase MLL.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MEN1	5.55	Potency	2818	nM	CHEMBL_ACT_4564092

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).